Abstract Number: 1737 • 2014 ACR/ARHP Annual Meeting
Altered Phenotype and Function of Senescent Regulatory T Cells in Rheumatoid Arthritis
Background/Purpose Immunosenescence accompanied by accumulation of senescent T cells is a hallmark feature in the pathogenesis of rheumatoid arthritis (RA). Here we characterize a novel senescent…Abstract Number: 1736 • 2014 ACR/ARHP Annual Meeting
Immune Related Adverse Events Associated with Anti-CTLA-4 Antibodies: Systematic Review and Meta-Analysis
Background/Purpose CTLA-4 is a costimulatory molecule that downregulates T-cell activation and promotes an immunotolerance, well known by rheumatologist since the use of Abatacept. Targeting CTLA-4…Abstract Number: 1735 • 2014 ACR/ARHP Annual Meeting
T–cell Tolerance Induction By the Glycosylated Type II Collagen Peptide-Based Vaccination in Murine Arthritis
Background/Purpose: Type II collagen (CII) has been suggested as a possible autoantigen in RA, since autoimmunity to CII is commonly detected in patients with RA.…Abstract Number: 1734 • 2014 ACR/ARHP Annual Meeting
IL-22 Plays a Significant Role in the Initiation and Augmentation of Th17-Dependent Experimental Arthritis
Background/Purpose Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive destruction of cartilage and bone. IL-22 and IL-22-producing T helper cells…Abstract Number: 1733 • 2014 ACR/ARHP Annual Meeting
Immunomodulatory Effects of Dietary Non-Digestible Oligosaccharides in T Cell-Mediated Autoimmune Arthritis
Background/Purpose: Accumulating evidence indicates the relevance of intestinal microbiota in shaping the immune response and supports its contribution to the development of autoimmune diseases. Prebiotic…Abstract Number: 1732 • 2014 ACR/ARHP Annual Meeting
Attenuation of Sclerodermatous Graft Versus Host Disease (sclGVHD) in IL4RA Receptor-Deficient Mice
Background/Purpose Scleroderma is a rare autoimmune disease characterized by the accumulation of fibrotic tissue in multiple organs including the skin, gut and lungs. To date,…Abstract Number: 1731 • 2014 ACR/ARHP Annual Meeting
Translocation of IGFBP-5 to the Nucleus and Its Interaction with Nucleolin Do Not Dictate Its Fibrotic Effects
Background/Purpose: Insulin-like growth factor binding protein (IGFBP)-5 is one of six IGFBPs. IGFBP-5 is the most conserved member of the family. IGFBP-5 levels are increased…Abstract Number: 1730 • 2014 ACR/ARHP Annual Meeting
Identification of Novel Scleroderma –associated Antigens and Development of an Autoantibody Assay Panel Enabling Their Subsequent Validation
Background/Purpose: Scleroderma (systemic sclerosis or SSc) has a highly variable clinical presentation and course resulting in difficulties for disease management. When SSc is suspected, autoantibodies…Abstract Number: 1729 • 2014 ACR/ARHP Annual Meeting
Adenosine A2A Receptor (A2AR) Promotes Collagen Type 3 Expression Via β-Catenin Activation
Background/Purpose A2AR stimulation promotes collagen 1 and 3 (Col1 and Col3) synthesis, principal mediators of fibrosis and scarring. We have recently demonstrated that the A2AR…Abstract Number: 1728 • 2014 ACR/ARHP Annual Meeting
Bromodomain Inhibitor JQ1 Modulates Collagen Processing and Ameliorates Bleomycin Induced Dermal Fibrosis in Mice
Background/Purpose: Systemic sclerosis (SSc) is a complex pro-inflammatory scarring disease, characterised by elevated deposition of extracellular matrix (ECM) proteins, in particular collagen type I. The…Abstract Number: 1727 • 2014 ACR/ARHP Annual Meeting
Poly(ADP-ribose) Polymerase-1 (PARP-1) Suppresses the Profibrotic Effects of Transforming Growth Factor â in Systemic Sclerosis
Background/Purpose The enzyme poly(ADP-ribose) polymerase-1 (PARP-1) transfers negatively charged ADP-ribose units from the donor β-NAD onto various substrate proteins either as mono- or oligomeric moieties…Abstract Number: 1726 • 2014 ACR/ARHP Annual Meeting
Therapeutic Efficacy of Mesenchymal Stem Cells in Diffuse Murine Hypochlorite-Induced Systemic Sclerosis
Background/Purpose Systemic sclerosis (SSc) is a rare intractable disease with unmet medical need and fibrosis-related mortality. Absence of efficient treatments has prompted to develop novel…Abstract Number: 1724 • 2014 ACR/ARHP Annual Meeting
Loss of IRF5 Ameliorates Tissue Fibrosis in a Murine Model of Systemic Sclerosis
Background/Purpose Systemic sclerosis (SSc) is a multisystem autoimmune disorder with clinical manifestations that result from fibrosis development, immune activation and vascular injuries. A genome-wide association…Abstract Number: 1725 • 2014 ACR/ARHP Annual Meeting
The SYK Inhibitor Fostamatinib Limits Tissue Damage and Fibrosis in a Bleomycin-Induced Scleroderma MOUSE MODEL
Background/Purpose The possible antifibrotic effects of various kinase inhibitors has been studied before in SSc. Spleen tyrosine kinase (Syk) is a protein tyrosine kinase which…Abstract Number: 1717 • 2014 ACR/ARHP Annual Meeting
Endothelial to Mesenchymal Transition Contributes to the Development of Pulmonary Vasculopathy in Systemic Sclerosis PAH
Background/Purpose Vascular complications in Scleroderma (SSc) patients are associated with high mortality, particularly in patients who develop pulmonary arterial hypertension (SSc-PAH). Vascular complications, thought to…
ACR Meeting Abstracts